|
|
Volumn 8, Issue 2, 2003, Pages 210-213
|
|
Signal transduction modulators for cancer therapy: From promise to practice?
|
|
Author keywords
Growth factors; Meeting report; New drug development; New drug targets; Receptor tyrosine kinases; Signal transduction modulators
|
|
Indexed keywords
1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE;
17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN;
2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE;
4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE;
6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE;
7 HYDROXYSTAUROSPORINE;
ANTINEOPLASTIC AGENT;
AP23451;
BEVACIZUMAB;
BORTEZOMIB;
CANERTINIB;
CETUXIMAB;
CPD 5;
CT 32228;
ERLOTINIB;
FLAVOPIRIDOL;
GEFITINIB;
GW 211;
IMATINIB;
IMC 1C11;
IMC 2C6;
IMC IC11;
MATUZUMAB;
N ACETYLCOLCHINOL PHOSPHATE;
PERTUZUMAB;
PROTEIN TYROSINE KINASE;
SEMAXANIB;
SIGNAL TRANDUCTION MODULATOR;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
TIPIFARNIB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VANDETANIB;
CANCER;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DRUG APPROVAL;
DRUG DESIGN;
DRUG SCREENING;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PRIORITY JOURNAL;
SIDE EFFECT;
SIGNAL TRANSDUCTION;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
ENZYME INHIBITORS;
HEALTH KNOWLEDGE, ATTITUDES, PRACTICE;
HUMANS;
NEOPLASMS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SIGNAL TRANSDUCTION;
UNITED STATES;
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;
|
|
EID: 0037260955
PISSN: 10837159
EISSN: None
Source Type: Journal
DOI: 10.1634/theoncologist.8-2-210 Document Type: Conference Paper |
|
Times cited : (4)
|
|
References (3)
|
